RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 1:54 AM
Followers: 436
Posts Today: 1
Views Today: 13649

CYDY Stock Quote & Tools

$0.2000 ▲ +0.0000 (+0.00%) As of Oct 7, 9:49 AM EDT
Last0.2000
$ Chg0.0000
Open0.1989
High0.2020
Beta1.4964
Year High0.397
Market Cap293.90M
P/B Ratio-2.68
EPS-0.03
Avg Vol (30d)1.60M
Volume115.3K
% Chg+0.00%
Prev Close0.2000
Low0.1989
VWAP0.20072
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. ohm20

    If data was forwarded it would be a request for guidance from FDA on whether to submit an

  2. ohm20

    With 23% bioavailability for Maraviroc I wonder what receptor coverage will be at in 7 days. I know

    (2)
  3. mtruong34

    Cytodyn crew can't be that stupid to keep making the same ambiguous mistake over and over, so it

    (2)
  4. TechGuru

    So, this is the news we were expecting. Main takeaway: the DSCM has found out that

    (24)
  5. Bw

    I prefer it this way as far as eua ... No point in making that public unless granted as it may

  6. ClosetInvestor

    could mean that Amarex submitted data to the FDA on behalf of Cytodyn while still keeping it

  7. jk1550

    Interesting. Thanks

  8. jeff67

    This is solid news. Now the number 1 question for management will be: Based on the guidance

  9. CrazyRon

    For an EUA to be granted, doesnt Cydy have to apply for it first?

  10. lorbas

    To my knowledge e.g. the dexamethasone study used a two-tailed to. For one-sided p-value you

    (1)
  11. CaptnAmerca

    Release the unblinded data, and PR the whole thing. That should help speed enrollment and put the

    (6)
  12. JLang

    The odds of the FDA giving any input yet are small / unlikely... This is the Data and Safety

    (13)
  13. jk1550

    lorbas, why do we need a 2-tailled distribution? The left hand side is totally of no use to this

  14. dfwl28

    B Patterson PR. excerpt Maraviroc, an oral medication, will be administered for seven

    (1)
  15. Eyedr

    I thought I read something from the FDA's website that the number of interim analyses has to be

  16. lorbas

    https://www.prnewswire.com/news-releases/incelldx-to-study-maraviroc-a-ccr5-antagonist-in-a-covid-1

  17. ohm20

    That Cytodyn is "seeking ongoing guidance from the U.S. Food and Drug Administration and regulatory

    (3)
  18. SAF

    I agree. At face value its hard to read the statement any other way. Definitely puts longs in

    (1)
  19. jk1550

    Blafarm, Please tell me what is really achieved if by chance we get the extra patients all enrolled

  20. Riztheinvestor

    Figured, good point.

  21. Riztheinvestor

    "If the DSMB reports that the clinical trial is likely to meet its endpoint and that they should

  22. CTMedic

    SAF, I believe you are 100% correct, that DSMC expects endpoint to be met, possibly at 75%

    (6)
  23. ohm20

    That EUA is based on risk/benefit analysis and leronlimab has an excellent safety profile and the

    (5)
  24. blafarm

    Odds will be high that none in the LLMab arm need a treatment past 14 days, imo... But it's

    (2)
  25. JLang

    Re: 42 day survival, with so many critical patients being in the ICU & on ventilators for > 20

    (1)
  26. Eyedr

    That's $3.24 USD +/- (2.74 euros) in case you don't have a conversion handy.

  27. Boatbuilder

    Pushes any positive news out to @ January 20th. Isnt that ironic.

    (2)
  28. generactor

    Ohm, do you think unblinding now would be a good idea given your post positing interim p-values

  29. invisioner

    So, they ARE changing the endpoint? It is confusing. It still says 28 days on clinicaltrials.gov.

  30. ohm20

    DSMC also requests another data review when enrollment reaches 293 patients (75%) to analyze

    (3)
  31. Eyedr

    https://www.bloomberg.com/quote/296:GR Up 15% on Stuttgart this morning. Woot,

  32. JLang

    Odds are that stat sig was met, but they're just shy of a p value justifying a halt... This is

    (1)
  33. lorbas

    Playing with some numbers for 75% enrollment... For n=294, Death Rate

  34. ohm20

    We should have at least 5 additional sites in the UK, 20 total. With 20 sites they would have to

    (1)
  35. blafarm

    Well, best case scenario might be enrollment in 4 weeks. That means the next interim enrollment

    (5)
  36. invisioner

    Wait, why 42? I am thinking 28. Where does the 42 come from?

  37. JLang

    Great summary of the issues and history of these failed CCR5 antagonists. But it isn't just CCR5

    (3)
  38. invisioner

    I totally agree with and also feel the frustration, but I don't think NP has a choice but to take

    (1)
  39. ohm20

    It's obviously 42 days after the 293rd patient is enrolled. The DSMC obviously thinks p value halt

    (8)
  40. invisioner

    And furthermore, if the trial was close to a p value to stop it, why did the FDA have it continue?

    (5)
  41. KenChowder

    Yes. Otherwise there would be no reason to add the additional interim.

  42. LaundryMoney

    I think because NP is not going to take this analysis lying down. If they are close enough that 293

    (4)
  43. blafarm

    Generactor Wrote:So the added 2 weeks to the monitoring period means the next interim look

    (5)
  44. ohm20

    The extension to 42 days should cover any decrease in the mortality rate. They must have seen

    (7)
  45. invisioner

    I do think that but it won't be until the end of December at the earliest, probably more like

    (1)
  46. invisioner

    That is so weird. Why didn't Nader just release this press release Thursday night instead of having

    (3)
  47. blafarm

    We have also seen the positive statistical effect of measuring mortality in clinical trials for

    (3)
  48. Daltondog

    ohm How does decreased overall death rate come into play?With lower numbers of deaths overall make

    (1)
  49. Respert24

    Now that we know the trial is continuing on, I'm hoping that Nader starts signing some deals. If

    (5)
  50. Doctor_Frank_Rocco

    Excellent article on zerohedge

    (4)

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Matador Resources CEO's Recent Stock Purchase Signals Confidence

Updated Category News Views 145

Matador Resources CEO Invests in Company Stock In a notable display of confidence in Matador Resources, CEO Joseph Wm Foran has made a significant insider buy, purchasing 2,000 shares of the company’s stock, valued at an impressive $92,500. This transaction was formally reported in a recent filing with the SEC, drawing attention from investors and analysts alike. Market...

Continue Reading
Novonesis Expands Market Reach with Strategic Acquisition

Updated Category News Views 298

Novonesis Acquires dsm-firmenich’s Share of Feed Enzyme Alliance Novonesis has a significant new chapter ahead as it has signed an agreement to take over dsm-firmenich’s portion of the Feed Enzyme Alliance. This agreement is valued at an impressive EUR 1.5 billion, marking a major strategic move for both companies. The dissolution of their collaborative relationship,...

Continue Reading
Star Bulk Carriers Corp. Achieves Impressive $81.3M Profit

Updated Category News Views 74

Star Bulk Carriers Corp. Reports Strong Third Quarter Results Star Bulk Carriers Corp. (NASDAQ: SBLK), a prominent player in the global shipping industry, has recently disclosed its financial performance for the third quarter of 2024. The company announced a striking net profit of $81.3 million during this period, reflecting its robust operational capabilities in the dry...

Continue Reading
Hancock Whitney Achieves $116 Million Net Income Amid Growth

Updated Category News Views 94

Hancock Whitney Corporation's Strong Financial Performance Hancock Whitney Corporation (NASDAQ: HWC) recently announced its financial results for the third quarter of 2024, revealing an impressive net income of $116 million, translating to $1.33 per share. This marks an increase of $1 million from the previous quarter. The bank's substantial performance highlights an...

Continue Reading
Hurricane Helene Approaches: Market Reactions from Generac and Duke Energy

Updated Category News Views 122

Hurricane Helene Approaches Florida: Brace for Impact Florida's gearing up as Hurricane Helene bears down on the state, intensifying from a tropical storm to a hurricane while skirting the Gulf of Mexico. With swirling winds clocking in at around 70 mph, this tempest poses serious risks that have residents on high alert. The Storm is Here: Key Details Currently making its...

Continue Reading